Form 4: ALX Oncology CFO Granted Stock Options

ALX Oncology's Chief Financial Officer, Harish Shantharam, was granted 600,000 stock options on January 21, 2025.

Summary

• Harish Shantharam, the Chief Financial Officer of ALX Oncology Holdings Inc., was granted 600,000 employee stock options on January 21, 2025.
• The exercise price of these options is $1.65 per share.
• The options vest over time, with one-fourth vesting on January 21, 2026, and the remaining vesting monthly over the following 47 months.
• The options expire on January 20, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one-fourth after one year and the remainder monthly is a typical vesting structure.
• The 10-year expiration period is also common for stock options.

Stakeholder Impact

• The stock option grant may have a positive impact on shareholder confidence by aligning the CFO's interests with the company's long-term success.
• The vesting schedule encourages the CFO's continued commitment to the company.

Key Dates

Keywords

stock options, executive compensation, insider trading, ALX Oncology, ALXO, CFO, Harish Shantharam